27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

Authors :: Hans Gelderblom
F. Bologna
C.Van Noort
R. Spinelli
Neeltje Steeghs
M.J.A. de Jonge
Jan Ouwerkerk
Jaap Verweij
F. Eskens
Patrizia Carpinelli
J.W.R. Nortier
Source :: European Journal of Cancer Supplements. 4:12
Publication Year :: 2006
Publisher :: Elsevier BV, 2006.

Subjects :: Cancer Research
Oncology
business.industry
Dose escalation
Aurora inhibitor
Medicine
In patient
Pharmacology
business
PHA-739358

Full Text Access

Tools